Novel Anticancer Agents: Molecular Mechanisms of Response and Resistance
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 11478
Special Issue Editors
Interests: cancer genomics; immunotherapy; phase 1 trials; clinical trial design
Interests: cancer; drug resistance; natural compound, chemotherapeutics; targeted therapy; drug delivery; nano therapy; 3D model; hypoxia; apoptosis; cell cycle; EMT
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The practice of oncology has been revolutionized by the advent of novel classes of drugs in the last decade: small molecules, immune checkpoint inhibitors, and antibody-drug conjugates. Despite the spectacular improvements in outcome allowed by these agents, primary or secondary resistance occurs in most patients, and the identification of predictive biomarkers remains a priority for cancer research. Biomarker identification has been favored by dramatic technological advancements, such as next-generation sequencing, proteomics and metabolomics, the development of increasingly sophisticated preclinical modeling systems such as organoids and patient-derived xenografts, and the development of computational methods for analyzing biomolecular data (bioinformatics).
This special issue will collect novel findings and reviews on established and novel biomarkers of response and resistance to anticancer drugs
Dr. Luca Mazzarella
Dr. Santosh Kumar Singh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- biomarker
- immunotherapy
- antibody-drug conjugate
- bioinformatics
- genomics
- metabolomics
- proteomics
- organoid
- patient-derived xenografts
- resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
